We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+35.53%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.48B
AUM Growth
+$248M
Cap. Flow
-$58.8M
Cap. Flow %
-3.97%
Top 10 Hldgs %
45.09%
Holding
80
New
10
Increased
13
Reduced
36
Closed
16

Top Buys

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$41.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$30.2M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$28.9M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$27.7M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$27M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$66.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$37.2M
4
TBPH icon
Theravance Biopharma
TBPH
+$22.6M
5
ARGX icon
argenx
ARGX
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBIO
51
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.63M 0.31%
454,549
-1
-0% -$8
XFOR icon
52
X4 Pharmaceuticals
XFOR
$393M
$4.4M 0.3%
8,425
-1,918
-19% -$1.06M
BOLD
53
DELISTED
Audentes Therapeutics, Inc
BOLD
$3.9M 0.26%
100,000
-21,797
-18% -$625K
HRTX icon
54
Heron Therapeutics
HRTX
$93.4M
$3.67M 0.25%
150,000
-15,682
-9% -$411K
SRRK icon
55
Scholar Rock
SRRK
$6.42B
$3.36M 0.23%
178,891
-31,187
-15% -$549K
ITRM
56
DELISTED
Iterum Therapeutics
ITRM
$3.2M 0.22%
26,553
-4,514
-15% -$414K
COLL icon
57
Collegium Pharmaceutical
COLL
$959M
$3.03M 0.2%
200,000
-45,370
-18% -$727K
ABEO icon
58
Abeona Therapeutics
ABEO
$394M
$2.94M 0.2%
16,000
-3,541
-18% -$633K
INCY icon
59
Incyte
INCY
$23.8B
$2.58M 0.17%
30,000
-221,335
-88% -$18M
ACRS icon
60
Aclaris Therapeutics
ACRS
$851M
$2.52M 0.17%
420,555
-57,500
-12% -$381K
SLDB icon
61
Solid Biosciences
SLDB
$866M
$2.3M 0.16%
16,667
-26,865
-62% -$6.73M
XLRN
62
DELISTED
Acceleron Pharma
XLRN
$1.86M 0.13%
40,000
-8,695
-18% -$382K
OTLKW
63
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$150K 0.01%
416,666
– –
CLRBW
64
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$5K ﹤0.01%
52,999
– –
CTMX icon
65
CytomX Therapeutics
CTMX
$734M
– –
-296,712
Closed -$4.48M
MGTX icon
66
MeiraGTx Holdings
MGTX
$1.19B
– –
-238,579
Closed -$2.3M
NKTR icon
67
CALL
Nektar Therapeutics
NKTR
$2.48B
– –
-16,667
Closed -$8.22M
OMER icon
68
CALL
Omeros
OMER
$934M
– –
-181,700
Closed -$2.02M
QTRX icon
69
Quanterix
QTRX
$179M
– –
-54,945
Closed -$1.01M
REPL icon
70
Replimune Group
REPL
$1.02B
– –
-467,792
Closed -$4.68M
SAGE
71
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-184,000
Closed -$17.6M
SGMO
72
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-194,274
Closed -$2.23M
TBPH icon
73
Theravance Biopharma
TBPH
$877M
– –
-884,916
Closed -$22.6M
GTHX
74
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-994,287
Closed -$19M
DRNA
75
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-3,481,471
Closed -$37.2M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Cormorant Asset Management held 80 positions worth $1.48B, up 20% from $1.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $58.8M in Q1 2019, closing 16 positions and reducing 36 holdings. Its most notable exit was TESARO, Inc., an estimated $66.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Lakefront Biotherapeutics American Depositary Shares worth $35M.

  • Cormorant Asset Management's largest Q1 2019 buy was Lakefront Biotherapeutics American Depositary Shares: 300,000 shares worth $35M.
  • Cormorant Asset Management added most to InflaRx in Q1 2019, an estimated $41.5M increase.
  • Cormorant Asset Management's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46M.
  • Cormorant Asset Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $66.8M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $1.48B portfolio in Q1 2019.
  • Cormorant Asset Management opened 10 new positions and closed 16 in Q1 2019.
  • Cormorant Asset Management's portfolio value rose 20% quarter-over-quarter to $1.48B.

Based on Cormorant Asset Management's 13F filing for Q1 2019, filed 15 May 2019.